PR-104A is a novel hypoxia-targeted anticancer agent, showing modest but significant selectivity for anoxic cells. References: Copp JN, Mowday AM, Williams EM, Guise CP, Ashoorzadeh A, Sharrock AV, Flanagan JU, Smaill JB, Patterson AV, Ackerley DF. Engineering a Multifunctional Nitroreductase for Improved Activation of Prodrugs and PET Probes for Cancer Gene Therapy. Cell Chem Biol. 2017 Mar 16;24(3):391-403. doi: 10.1016/j.chembiol.2017.02.005. Epub 2017 Mar 2. PubMed PMID: 28262557.

纯度：≥98%

CAS：680199-06-8